Tryfonidis, Konstantinos
Senkus, Elzbieta
Cardoso, Maria J.
Cardoso, Fatima
Article History
First Online: 10 February 2015
Change Date: 14 April 2015
Change Type: Correction
Change Details: In the version of this article originally published online and in print, the word 'radiotherapy' was missing in figure 1 from one of the boxes. Additionally, several of the boxes had been merged, which meant the order of treatments was unclear. The figure has now been corrected for the HTML and PDF versions of the article published online.
Competing interests
: E.S. is an advisory board member for Roche, has received travel support from Novartis and belongs to the speakers' bureau for AstraZeneca, GSK and Roche. F.C. has received Consultant/honouraria and is an advisory board member for Astellas, Astra-Zeneca, Celgene, Daiichi-Sankyo, Eisai, Genentech/Roche, GE Oncology, GlaxoSmithKline, Merck-Sharp, Merus, Novartis, Pfizer, and Sanofi. K.T. and M.J.C. have no competing interests.